Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Patients not eligible for surgical resection, liver transplantation, local ablation techniques or chemoembolisation and with histologically proven liver carcinoma whenever possible or combination of radiologically documented hypervascular liver tumour and α foeto protein level ≥ 400 ng/ml~* Signed and dated approved patient informed consent form prior to enrollment into the study~Exclusion Criteria:~* ECOG performance status \> 2~* Inadequate organ function:~  * Neutrophils (ANC) \< 1,500/mm3~ * Hemoglobin \< 10g/dl~ * Platelets \< 100,000/mm3~ * Total bilirubin \> 1.5 x ULN~ * ASAT, ALAT \> 3 x ULN~ * Creatininemia \> 1.5 x ULN (or ≥ 2.0 mg/dl)~ * INR \> 1.6~ * Liver cirrhosis Child Pugh B or C (score \> 6)~ * HbA1C \> 8%~* No measurable or evaluable tumoral lesion~* Patients not eligible for sorafenib therapy and for whom this therapy cannot be postponed by 3 weeks (during AVE1642 single treatment period) in dose escalation part~* Prior exposure to an anti-IGF-1R class compound~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Level -1 (Type: EXPERIMENTAL): 0.5 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
- Dose Level 1 (Type: EXPERIMENTAL): 1 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
- Dose Level 2 (Type: EXPERIMENTAL): 3 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
- Dose Level 3 (Type: EXPERIMENTAL): 6 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
- Dose Level 4 (Type: EXPERIMENTAL): 12 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
- Dose Level 5 (Type: EXPERIMENTAL): 18 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
- Combination cohort 1 (Type: EXPERIMENTAL): AVE1642 selected dose in combination with sorafenib
- Combination cohort 2 (Type: EXPERIMENTAL): AVE1642 selected dose in combination with erlotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).